What is the efficacy of Regorafenib combined with PD1?
Regorafenib(Regorafenib) combined with inhibitors of vascular endothelial growth factor and programmed cell death protein 1 (PD1) pathways has shown efficacy in a variety of cancers, but the disease-specific and drug-specific benefit mechanisms remain unclear. The efficacy of the combination of regorafenib and PD1 blockade was tested in a mouse model of hepatocellular carcinoma (HCC), showing that it can increase intratumoral CXCR3+CD8 by normalizing tumor vasculature and increasing CXCL10 expression in HCC cells. T cell infiltration, thereby inhibiting tumor growth and increasing survival.

Combined treatment with regorafenib/-PD1 increased survival in a regorafenib dose-dependent manner compared with regorafenib or PD1 alone. Combination therapy increased tumor tissue uptake of regorafenib by normalizing HCC vasculature and increasing CD8 T cell infiltration and activation at moderate doses of regorafenib. In mice lacking functional T cells, the efficacy of regorafenib/anti-PD1 therapy was compromised. Regorafenib treatment increased the transcription and protein expression of tumor-infiltrating lymphocytes expressing cxcl 10 - a CXCR3 ligand - in the blood of murine HCC and HCC patients.
RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)